ArticleCancer management and research2025
A Machine Learning Model for Predicting Breast Cancer Recurrence and Supporting Personalized Treatment Decisions Through Comprehensive Feature Selection and Explainable Ensemble Learning.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Perioperative machine learning models with SHAP interpretation for predicting adverse outcomes in breast cancer surgery.Frontiers in surgery · 2026Article
- Ensemble machine learning for predicting costs and cost influencers in breast cancer surgery.BMC health services research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study investigates the efficiency of a machine learning model integrating least absolute shrinkage and selection operator (LASSO) feature selection with ensemble learning in predicting recurrence risk and supporting personalized treatment decisions in breast cancer patients. Materials and Methods: Clinical data from 1,131 breast cancer patients (1,056 nonrecurrent and 75 recurrent) were collected from Kaohsiung Medical University Hospital's electronic health record system. After preprocessing and standardization, LASSO was applied for feature selection. An ensemble learning model was developed based on multiple machine learning algorithms, with SHAP (Shapley additive explanations) used for interpretability. Results: The ensemble model achieved an AUC of 0.817, outperforming the best single model (AUC 0.711), demonstrating improved predictive accuracy and stability. LASSO identified six key predictors: regional lymph node positivity, ER status, Ki-67, lymphovascular invasion, tumor size, and age at diagnosis. SHAP analysis enhanced transparency by quantifying the contribution of each feature to recurrence risk, improving clinical understanding. Conclusion: This LASSO-enhanced ensemble model significantly improves the accuracy and interpretability of breast cancer recurrence prediction. By identifying individualized recurrence risks through SHAP analysis, the model supports more precise, data-driven clinical decision-making. These findings demonstrate its potential as a clinical decision support tool for guiding personalized treatment strategies, contributing to more effective breast cancer management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.